CAVATAK™ bladder cancer positive preliminary data

Source: ASX and Media Release

Viralytics Limited (ASX:VLA, OTC:VRACY) has received positive preliminary data in bladder cancer in its collaboration with Professor Hardev Pandha’s research team at The University of Surrey in the United Kingdom.

Viralytics to endeavour to also target bladder cancer application with melanoma, lung and prostate cancer.